Aurora Spine commenced full commercial release of its SiLO TFX MIS Sacroiliac Joint Fixation Device system, which received FDA 510(k) marketing clearance just under one year ago.
SiLO TFX MIS is intended for sacroiliac joint fusion for conditions including sacroiliac joint disruptions and degenerative sacroiliitis. The system includes a Transfixing-Cone, ilium screw, sacrum screw and associated instrumentation. SiLO TFX implants are designed to transfix the sacrum and ilium, providing stability for bony fusion.
Petra Lopizzo, Aurora’s Director of Operations, said, “The release of SiLO TFX is proceeding smoothly and rapidly as we deploy more instruments sets and implants into the field. I am pleased with the teamwork between Engineering, Operations and Marketing on the full release of the SiLO TFX system.”
Aurora Spine commenced full commercial release of its SiLO TFX MIS Sacroiliac Joint Fixation Device system, which received FDA 510(k) marketing clearance just under one year ago.
SiLO TFX MIS is intended for sacroiliac joint fusion for conditions including sacroiliac joint disruptions and degenerative sacroiliitis. The system includes a...
Aurora Spine commenced full commercial release of its SiLO TFX MIS Sacroiliac Joint Fixation Device system, which received FDA 510(k) marketing clearance just under one year ago.
SiLO TFX MIS is intended for sacroiliac joint fusion for conditions including sacroiliac joint disruptions and degenerative sacroiliitis. The system includes a Transfixing-Cone, ilium screw, sacrum screw and associated instrumentation. SiLO TFX implants are designed to transfix the sacrum and ilium, providing stability for bony fusion.
Petra Lopizzo, Aurora’s Director of Operations, said, “The release of SiLO TFX is proceeding smoothly and rapidly as we deploy more instruments sets and implants into the field. I am pleased with the teamwork between Engineering, Operations and Marketing on the full release of the SiLO TFX system.”
Copy to clipboard 
